Completed PHASE3 INTERVENTIONAL 3-arm NCT00771251

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

A Study of Golimumab (CNTO148) Monotherapy in Patients With Active Rheumatoid Arthritis

Sponsor: Janssen Pharmaceutical K.K.

Updated 7 times since 2017 Last updated: Nov 2, 2015 Started: May 31, 2008 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00771251, this PHASE3 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Janssen Pharmaceutical K.K., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Jan 2026 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutical K.K.
Tanabe Pharma Corporation

Data source: Janssen Pharmaceutical K.K.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asahikawa, Japan , Ayauta, Japan , Azumino, Japan , Chiba, Japan , Fuchū, Japan , Fukui, Japan , Fukuoka, Japan , Fukushima, Japan , Gifu, Japan , Goshogawara, Japan and 57 more locations